Affimed ROA 2014-2024 | AFMDQ
Current and historical return on assets (ROA) values for Affimed (AFMDQ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Affimed ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-09-30 |
$-0.08B |
$0.04B |
-108.83% |
| 2024-06-30 |
$-0.09B |
$0.06B |
-94.05% |
| 2024-03-31 |
$-0.10B |
$0.08B |
-88.70% |
| 2023-12-31 |
$-0.12B |
$0.11B |
-81.71% |
| 2023-09-30 |
$-0.13B |
$0.13B |
-76.53% |
| 2023-06-30 |
$-0.12B |
$0.15B |
-60.82% |
| 2023-03-31 |
$-0.11B |
$0.18B |
-47.19% |
| 2022-12-31 |
$-0.09B |
$0.21B |
-38.98% |
| 2022-09-30 |
$-0.08B |
$0.24B |
-33.63% |
| 2022-06-30 |
$-0.09B |
$0.28B |
-34.08% |
| 2022-03-31 |
$-0.09B |
$0.22B |
-34.17% |
| 2021-12-31 |
$-0.07B |
$0.27B |
-23.63% |
| 2021-09-30 |
$-0.06B |
$0.26B |
-21.73% |
| 2021-06-30 |
$-0.05B |
$0.30B |
-19.33% |
| 2021-03-31 |
$-0.04B |
$0.33B |
-18.85% |
| 2020-12-31 |
$-0.05B |
$0.20B |
-34.50% |
| 2020-09-30 |
$-0.04B |
$0.13B |
-37.45% |
| 2020-06-30 |
$-0.05B |
$0.11B |
-44.65% |
| 2020-03-31 |
$-0.05B |
$0.11B |
-43.74% |
| 2019-12-31 |
$-0.04B |
$0.13B |
-32.39% |
| 2019-09-30 |
$-0.01B |
$0.10B |
-9.40% |
| 2019-06-30 |
$-0.01B |
$0.11B |
-12.09% |
| 2019-03-31 |
$-0.01B |
$0.13B |
-11.28% |
| 2018-12-31 |
$-0.02B |
$0.14B |
-26.51% |
| 2018-09-30 |
$-0.04B |
$0.06B |
-64.86% |
| 2018-06-30 |
$-0.04B |
$0.07B |
-59.61% |
| 2018-03-31 |
$-0.04B |
$0.08B |
-60.91% |
| 2017-12-31 |
$-0.04B |
$0.05B |
-63.06% |
| 2017-09-30 |
$-0.03B |
$0.05B |
-58.15% |
| 2017-06-30 |
$-0.03B |
$0.06B |
-58.37% |
| 2017-03-31 |
$-0.03B |
$0.06B |
-55.74% |
| 2016-12-31 |
$-0.04B |
$0.05B |
-51.66% |
| 2016-09-30 |
$-0.04B |
$0.06B |
-47.21% |
| 2016-06-30 |
$-0.03B |
$0.07B |
-41.77% |
| 2016-03-31 |
$-0.03B |
$0.09B |
-37.15% |
| 2015-12-31 |
$-0.02B |
$0.09B |
-32.97% |
| 2015-09-30 |
$-0.02B |
$0.07B |
-35.63% |
| 2015-06-30 |
$-0.01B |
$0.08B |
-8.30% |
| 2015-03-31 |
$0.02B |
$0.04B |
46.34% |
| 2014-12-31 |
$0.00B |
$0.06B |
0.00% |
| 2014-09-30 |
$-0.01B |
$0.06B |
-56.25% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
